The future has arrived #CUBETechFair

CUBE10 - 12 May 2017, Berlin, Germany.
Startups are setting up, speakers are tweaking their talks, and CUBE Tech Fair is ready for you... The inaugural CUBE Tech Fair kicks off tomorrow, and what a show they have for you. CUBE Tech Fair has brought the Crème de la Crème of the tech world to Berlin.

Over 300 startups from our ecosystem will be exhibiting, in addition to pitching for a €1 million prize in CUBE Challenge. The final round will be judged by Apple Co-Founder, Steve Wozniak.

Let's welcome keynote speeches by:

  • Pablos Holman (Founder of Intellectual Ventures Laboratory, notorious hacker)
  • Michael Müller (Mayor of Berlin)
  • Steve Wozniak (Co-Founder of Apple),
  • Robin Wright (Award-winning actress, tech activist),
  • Brigitte Zypries (Federal Minister of Economic Affairs and Energy)

The fireside chats, keynotes speeches, and panel discussions will deep-dive into specific industry areas. Topics include:

  • Infrastructure & Interconnectivity
  • Digital Health & Life Sciences
  • Machinery & Manufacturing
  • Cybersecurity & Hacking
  • Climate Change & Smart Energy Systems
  • Blockchain Innovations and more!

The Welcome Reception has filled up fast, and organisers already have exceptional guests including top startups, corporates and investors - and for good reason. Come, network and enjoy food tech at it's best - CUBE will be serving up bites from the incredible German Michelin-starred chef Christian Lohse. And on top of that all the ingredients are being provided by anti-food-waste startup SirPlus.

Don't have a booked seat? No problem! The event is still open to all Tech Fair badge holders!

On Thursday night, organisers take to the CityCube's terrace for the official Tech Fair party - they will of course be bringing Berlin's party spirit to the tech world.

Still don't have a ticket?! Get one now!

World Pharma News readers can benefit from an exclusive discount - get 30% off the ticket price using our unique promo code worldpharmanewsCUBE17 when you register online here.

About CUBE
CUBE is a Berlin-based global innovation ecosystem that aims to promote, create and foster partnerships between industry players and startups in life sciences & digital health, machinery & manufacturing as well as infrastructure & connectivity. Being part of the CUBE ecosystem allows all participants to collaborate on innovative products and ideas in response to concrete industry needs.

The annual CUBE Tech Fair, our flagship event, will take place for the first time in May 2017. For further information, please visit http://tech-fair.cube-global.com.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...